Oncternal Therapeutics Inc ONCT:NASDAQ

Set AlertOptionsStreaming Charts
Last Price$1.22Cboe Real-Time Last Sale as of 3:42PM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.06(5.17%)
Bid (Size)$1.22 (100)
Ask (Size)$1.23 (1,618)
Day Low / High$1.17 - 1.24
Volume614.8 K
Sell
Buy

Oncternal Therapeutics Shifts Priority to Zilovertamab From ONCT-216; Shares Fall

10:02AM ET 4/13/2022 MT Newswires
Oncternal Therapeutics (ONCT) said Wednesday that it has deprioritized the development of ONCT-216 to reallocate resources to zilovertamab, which is currently being evaluated in its treatment of patients with mantle cell lymphoma or chronic lymphocytic leukemia.

The biopharmaceutical company said it has discontinued enrollment in a phase 1/2 study evaluating ONCT-216 in patients with relapsed or refractory Ewing sarcoma. Oncternal expects to initiate a phase 3 trial of zilovertamab in Q3.

ONCT shares were down more than 1% Wednesday morning.

Price: 1.15, Change: -0.01, Percent Change: -1.29

Most Popular Keyword Searches

NFLX bac znga Enter Symbol or Name F tsla GPRO BABA amd AAPL TWTR GE amzn ddd spy FNMA JCP FB MSFT MJNA